GSK 3039294
Based on 1 Customer Validation
GSK3039294 is an orally active pro-drug of Miridesap (HY-101861), a circulating serum amyloid P component depleter. GSK3039294 undergoes hydrolysis to form miridesap via a monoester intermediate. GSK3039294 can be used for the research of systemic amyloidosis.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 1819986-22-5
- Formula: C30H44N2O14
- Molecular Weight:656.68
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Peptidomimetic Library
HY-L033
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
GSK3039294 (3 μM; 90 min) exhibits high passive permeability through MDCK-II cell monolayers[1].
GSK3039294 (30.3 ng/mL; 0-30 min) is rapidly hydrolyzed to miridesap in rat, dog, and human liver microsomes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
GSK3039294 (5-1000 mg/kg; p.o.; repeat gavage for up to 28 days) administered orally to male Marshall beagle dogs results in rapid conversion to miridesap, with an equivalent oral bioavailability of Miridesap of 22% at a 5 mg/kg single dose and consistent high Miridesap exposure during repeat dosing[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Han-Wistar (male, 10-12 weeks old, 200-250 g)[1]
-
Dosage:3-1000 mg/kg (p.o.)
-
Administration:p.o.; single gavage/repeat gavage for up to 6 months
-
Result:Achieved equivalent oral bioavailability of miridesap of 56-80% at 3 mg/kg single oral dose, 36-58% at 10 mg/kg single oral dose, 50% at 10 mg/kg single oral dose, 37% at 30 mg/kg single oral dose, and 30% at 100 mg/kg single oral dose.
Showed roughly dose-proportional increases in miridesap exposure and maximum plasma concentration (Cmax) up to 100 mg/kg single oral dose.
Was not detected in rat blood up to 24 hours post-oral administration at any dose, indicating rapid in vivo cleavage to miridesap.
Detected monoester intermediate only at the 100 mg/kg single oral dose, up to 2-4 hours post-administration.
Resulted in consistent high exposure to miridesap with repeat oral doses of 100, 300, and 1000 mg/kg, though exposure was less than dose-proportional at these higher doses.
-
Animal Model:Marshall beagle (male, at least 10 months old, 6-15 kg)[1]
-
Dosage:5 mg/kg (p.o., single); 100-1000 mg/kg (p.o., repeat)
-
Administration:p.o.; single gavage/repeat gavage for up to 28 days
-
Result:Achieved equivalent oral bioavailability of miridesap (active metabolite) of 22% at 5 mg/kg single oral dose.
Was not detected in dog blood up to 24 hours post-single oral administration; monoester intermediate was detected up to 2 hours post-administration at very low concentrations.
Resulted in consistent high exposure to miridesap with repeat oral doses of 100, 300, and 1000 mg/kg, though exposure was less than dose-proportional at these higher doses.
Was quantifiable in dog blood during repeat dosing, with exposure increasing with dose and an "intravenous-like" rapid decline, with very low levels detectable up to 24 hours.
Chemical Information
-
CAS No. 1819986-22-5
-
Appearance Solid
-
Molecular Weight 656.68
-
Formula C30H44N2O14
-
Color White to off-white
-
SMILES
O=C(N1[C@@H](C(OCOC(OC2CCOCC2)=O)=O)CCC1)CCCCC(N3CCC[C@@H]3C(OCOC(OC4CCOCC4)=O)=O)=O
-
Synonyms
GSK294; amyloid P-IN-1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : ≥ 34 mg/mL (51.78 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5228 mL | 7.6141 mL | 15.2281 mL | 38.0703 mL |
| 5 mM | 0.3046 mL | 1.5228 mL | 3.0456 mL | 7.6141 mL | |
| 10 mM | 0.1523 mL | 0.7614 mL | 1.5228 mL | 3.8070 mL | |
| 15 mM | 0.1015 mL | 0.5076 mL | 1.0152 mL | 2.5380 mL | |
| 20 mM | 0.0761 mL | 0.3807 mL | 0.7614 mL | 1.9035 mL | |
| 25 mM | 0.0609 mL | 0.3046 mL | 0.6091 mL | 1.5228 mL | |
| 30 mM | 0.0508 mL | 0.2538 mL | 0.5076 mL | 1.2690 mL | |
| 40 mM | 0.0381 mL | 0.1904 mL | 0.3807 mL | 0.9518 mL | |
| 50 mM | 0.0305 mL | 0.1523 mL | 0.3046 mL | 0.7614 mL |
GSK 3039294 Related Classifications
Cat. No.: HY-19771
Powered by Bioz
- GSK 3039294
- 1819986-22-5
- GSK294
- amyloid P-IN-1
- GSK3039294
- GSK-3039294
- GSK 294
- GSK-294
- Amyloid-β
- MDCK-II cell monolayers
- human liver microsomes
- epithelial cell monolayers
- liver microsomes
- serum amyloid P component
- systemic amyloidosis
- intestinal microsomes
- dogs
- human intestinal microsomes
- male rats
- Inhibitor
- inhibitor
- inhibit